Format

Send to

Choose Destination
J Clin Pharm Ther. 2016 Aug;41(4):447-448. doi: 10.1111/jcpt.12406. Epub 2016 Jun 15.

Chemotherapy (platinum and pemetrexed) in combination with erlotinib in non-small cell lung cancer induces major gastrointestinal toxicity: two case reports from the FLARE/GFPC 03-2013 study.

Author information

1
Department of Pharmacology, CHU de Caen, Caen, France.
2
Department of Clinical Research, Centre François Baclesse, Caen, France.
3
Department of Clinical Research, CHU de Caen, Caen, France.
4
Department of Pneumology, Meulan-Les Mureaux Intercommunal Hospital, Meulan en Yvelines, France.
5
Department of Medical Oncology, Institut Paoli Calmettes, Marseille, France.
6
Department of Oncology, Centre François Baclesse, Caen, France.

Abstract

WHAT IS KNOWN AND OBJECTIVE:

A randomized phase III study was designed to assess the efficacy and safety of second-line platinum-based chemotherapy with or without erlotinib in non-small cell lung cancer (NSCLC) with EGFR-activating mutation after secondary resistance to EGFR-TKIs (epidermal growth factor receptor tyrosine kinase inhibitors).

CASE SUMMARY:

We report herein two of the first three patients who presented with major gastrointestinal toxicities in the experimental arm of the trial.

WHAT IS NEW AND CONCLUSION:

Pending further data, it would seem safer to administer EGFR-TKIs and chemotherapy sequentially rather than concomitantly.

KEYWORDS:

chemotherapy; erlotinib; gastrointestinal toxicity; non-small cell lung cancer

PMID:
27306517
DOI:
10.1111/jcpt.12406

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center